NCI - Center for Cancer Research
NCI - Center for Cancer Research
Bethesda, Maryland, United States13 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-10-09 | NCT03141684 | |
| Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment | cancer, neoplasm | Active, not recruiting | Not stated | 2026-09-30 | NCT02243592 | |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Papillary renal cell carcinoma, sporadic, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, hereditary leiomyomatosis and renal cell cancer, kidney cancer, kidney disorder, neoplasm, papillary renal cell carcinoma, renal cell carcinoma, urinary system disorder | Recruiting | Phase 2 | 2026-09-29 | NCT04981509 | |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube carcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, primary peritoneal carcinoma, primary peritoneal serous adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-29 | NCT02345265 | |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bladder squamous cell carcinoma, bladder transitional cell carcinoma, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, kidney medullary carcinoma, male reproductive organ cancer, male reproductive system disorder, neoplasm, penile carcinoma, penile disorder, penile neoplasm, renal cell carcinoma, renal pelvis urothelial carcinoma, sarcomatoid renal cell carcinoma, squamous cell carcinoma of penis, ureter cancer, ureter transitional cell carcinoma, ureteral disorder, urethra neoplasm, urethra transitional cell carcinoma, urethral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary bladder small cell neuroendocrine carcinoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-09-10 | NCT02496208 | |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-09 | NCT06311227 | |
| Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma | nasopharyngeal squamous cell carcinoma | Active, not recruiting | Phase 1 | 2026-08-03 | NCT03803774 | |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm, refractory hairy cell leukemia | Recruiting | Phase 1 / Phase 2 | 2026-07-31 | NCT06965114 | |
| Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, clear cell sarcoma, connective tissue neoplasm, dedifferentiated chondrosarcoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-07-31 | NCT04458922 | |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 2 | 2026-07-31 | NCT03896503 | |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 2 | 2026-06-11 | NCT03375307 | |
| Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-05-28 | NCT02275533 | |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 1 | 2026-05-13 | NCT05353439 |